Mariem Salma Lejwad Abdoudaim

Dr. Mariem Salma Lejwad Abdoudaim

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MAMariem Salma Lejwad Abdoudaim
Mariem Salma Lejwad Abdoudaim
MAMohamed Vall Mohamed Abdellahi
Mohamed Vall Mohamed Abdellahi
NBNacer dine Mohamed Baba
Nacer dine Mohamed Baba
RBRalph Sydney Mboumba Bouassa
Ralph Sydney Mboumba Bouassa
Mohamed Lemine Cheikh Brahim AHMEDMohamed Lemine Cheikh Brahim AHMED
Mohamed Lemine Cheikh Brahim AHMED
LBLaurent Bélec
Laurent Bélec
Cervical cancer related to high-risk human papillomavirus (HR-HPV) is the second female cancer in Mauritania (Northwest Sahelian Africa). We assessed the distribution of HPV genotypes in Mauritanian women with high-grade cervical intraepithelial neoplasia (CIN2/3) or invasive cervical cancer (ICC). A prospective study was conducted in the Centre Hospitalier National, Nouakchott, Mauritania, to collect cervical biopsies among women suspected of CIN2/3 or cancer. HPV DNA detection and genotyping were carried out from formalin-fixed, paraffin-embedded biopsies using multiplex PCR (Human Papillomavirus Genotyping Real-Time PCR Kit, Bioperfectus Technologies Co., Taizhou, China). Fifty biopsies were included from women (mean age: 56.7 years) suffering from CIN2/3 (28.0%) and ICC (72.0%) which corresponded to 32 (64.0%) squamous cell carcinomas (SCC) and 4 (8.0%) adenocarcinomas (ADC). HPV DNA detection was successful in 47 (94.0%) samples. The most prevalent HR-HPV genotypes were HPV-45 (40.4%), HPV-16 (38.3%), HPV-39 and HPV-52 (23.4%), HPV-33 (17.0%), HPV-18 (14.9%), HPV-35 (4.2%), and HPV-56 (2.1%). The majority (93.6%) of HPV-positive biopsies contained at least one HPV type covered by the 9-valent Gardasil-9® vaccine, and 40.9% were infected by multiple vaccine HPV genotypes. To eradicate cervical cancer in Mauritania, prophylactic HPV vaccination must be combined with primary molecular screening of cervical HR-HPV infection.

17 November 2025 in Health Science Reports
Verified
Journal Article
Open access
MAMariem Salma Lejwad Abdoudaim
Mariem Salma Lejwad Abdoudaim
LBLaurent Bélec
Laurent Bélec
MAMohamed Lemine Cheikh Brahim Ahmed
Mohamed Lemine Cheikh Brahim Ahmed
NBNacer Dine Mohamed Baba
Nacer Dine Mohamed Baba
RBRalph Sydney Mboumba Bouassa
Ralph Sydney Mboumba Bouassa
MAMariem Salma Lejwad Abdoudaim
Mariem Salma Lejwad Abdoudaim
Background and Aims: We herein evaluated whether intra‐tissue HPV viral load may constitute a triage biomarker to differentiate between high‐grade precancerous cervical lesions from intra cervical cancer (ICC). Methods: 50 biopsy samples prospectively obtained from women living in Mauritania suffering from high‐grade cervical intraepithelial neoplasia (CIN2/3), adenocarcinoma (ADC) or squamous cell carcinoma (SCC) were analysed for HPV genotyping and quantitation carried out using Bioperfectus Multiplex Real Time Human Papillomavirus Genotyping Real Time PCR assay. Results: HPV‐positive results were detected in 47 biopsies (12 CIN2/3 and 35 ICC, including 4 ADC and 31 SCC). The cumulative HPV viral loads of any HPV and high risk‐HPV (HR‐HPV) in ICC were significantly higher than those in CIN2/3 ( p < 0.002 for any HPV; 0.02 for HR‐HPV). The cumulative viral loads of any HPV and HR‐HPV possessed a good discriminatory ability to differentiate between CIN2/3 and ICC, with optimal cutoffs ranging from 4.38 (any HPV) to 4.85 (HR‐HPV) copies per 10,000 cells. Conclusion: Our observations show that cumulative HPV viral load in cervical tissue may constitute a relevant biomarker associated with the severity of HPV‐related cervical lesions. HPV viral load in cervical tissue could be used as a triage tool for aggressive ICC in advanced cervical lesions.